Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 8Other hematologic neoplasm 7Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 3Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Leukoplakia, Oral 2Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Head and Neck Neoplasms 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pioglitazone × Head & Neck × Clear all
NCT00099021 2022-02-11

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 6 charts
Head & Neck

Head and Neck Neoplasms, Leukoplakia, Oral

NCT01655719 2017-10-26

Pioglitazone in Thyroid Cancers

University of Michigan

Phase 2 Completed
1 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

NCT00951379 2016-04-06

Pioglitazone for Oral Premalignant Lesions

National Cancer Institute (NCI)

Phase 2 Terminated
52 enrolled 23 charts
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡